

Assoc. Prof. NEYRAN KERTMEN

Personal Information

Office Phone: [+90 312 305 2927](tel:+903123052927)

Office Phone: [+90 312 305 2929](tel:+903123052929)

Fax Phone: [+90 312 305 2929](tel:+903123052929)

Email: neyran.kertmen@hacettepe.edu.tr

Education Information

Post Doctorate of Medicine, Hacettepe Üniversitesi, Tıp Fakültesi , Medikal Onkoloji , Turkey 2010 - 2013

Expertise In Medicine, S.B.Dışkapı Yıldırım Beyazıt.E.A.H, İç Hastalıkları , İç Hastalıkları , Turkey 2004 - 2009

Post Graduate, Gazi Üniversitesi, Tıp Fakültesi , Tıp Fakültesi , Turkey 1998 - 2004

Foreign Languages

English, B2 Upper Intermediate

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Academic Titles / Tasks

Assistant Professor, Hacettepe Üniversitesi, Kanser Enstitüsü , Klinik Onkoloji Anabilim Dalı, 2016 - Continues

Expert, Hacettepe Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2013 - 2016

Courses

KLİNİK EĞİTİM (CLINICAL TUTORIAL), Post Graduate, 2016 - 2017, 2017 - 2018

YATAK BAŞI DOKTOR EĞİTİMİ (BEDSIDE), Post Graduate, 2016 - 2017, 2017 - 2018

KONSULTAN VİZİTİ (ROUNDS WITH THE CONSULTANT), Post Graduate, 2016 - 2017, 2017 - 2018

PRÖPEDÖTİK, Post Graduate, 2016 - 2017, 2017 - 2018

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma**
BAŞ O., Ozbek A., Guven D., Aktepe O., KILIÇ L., KERTMEN N., ERMAN M.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, pp.1230-1233, 2020 (Journal Indexed in SCI)
- II. **Depression and anxiety in oncology nurses.**
Keskin O., Oktay E., Turan M., Kertmen N., Tanriverdi O., Imamoglu G. I. , Yuce D., Ozturk B., Ata O.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, 2018 (Journal Indexed in SCI)

- III. **Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancers**
Karakas Y, KERTMEN N, LAÇİN Ş, Aslan A, DEMİR M, ATEŞ Ö, AKSOY S, Altundag K.
JOURNAL OF BUON, vol.22, pp.623-627, 2017 (Journal Indexed in SCI)
- IV. **Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience**
Sarici F, BABACAN T, Buyukhatipoglu H, Balakan O, SEVER A. R. , KERTMEN N., Unlu O, ATEŞ Ö, DIKER O., AKIN S., et al.
JOURNAL OF BUON, vol.21, pp.826-831, 2016 (Journal Indexed in SCI)
- V. **Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors**
ATEŞ Ö, SOYLU C., BABACAN T., Sarici F., KERTMEN N., Allen D., SEVER A. R. , Altundag K.
SPRINGERPLUS, vol.5, 2016 (Journal Indexed in SCI)
- VI. **Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer**
ATEŞ Ö, BABACAN T, KERTMEN N., Sarici F., Cenoli A., AKIN S., Karakas Y., KILIÇKAP S., Ozisik Y., SEVER A. R. , et al.
JOURNAL OF BUON, vol.21, pp.375-381, 2016 (Journal Indexed in SCI)
- VII. **Anthracyclin - Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75**
Sarici F., KERTMEN N., Aslan A. C. , Tasdemir V., BABACAN T., KILIÇKAP S., ÖZDEMİR E., BARIŞTA İ., Turker A., Kars A.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, pp.89-95, 2016 (Journal Indexed in SCI)
- VIII. **Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer**
BABACAN T., Efe O., Hasirci A. S. , Demirci F., Buyukhatipoglu H., Balakan O., Sarici F., KERTMEN N., Esin E., AKIN S., et al.
TUMORI J, vol.101, pp.418-423, 2015 (Journal Indexed in SCI)
- IX. **The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality**
Solak M., Turkoz F. P. , Keskin O., AKSOY S., BABACAN T., Sarici F., KERTMEN N., SEVER A. R. , Altundag K.
JOURNAL OF BUON, vol.20, pp.737-745, 2015 (Journal Indexed in SCI)
- X. **Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis**
BABACAN T., Buyukhatipoglu H., Balakan O., KERTMEN N., Suner A., Sarici F., AKIN S., ATEŞ Ö, Karakas Y., Aslan A., et al.
JOURNAL OF BUON, vol.20, pp.479-486, 2015 (Journal Indexed in SCI)
- XI. **A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer**
Buyukhatipoglu H., BABACAN T., KERTMEN N., Balakan O., Suner A., ATEŞ Ö, Sarici F., Aslan A., DIKER O., Tasdemir V., et al.
JOURNAL OF BUON, vol.20, pp.22-27, 2015 (Journal Indexed in SCI)
- XII. **Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab**
ATEŞ Ö, Sunar V., BABACAN T., AKIN S., KERTMEN N., Altundag K.
JOURNAL OF BUON, vol.20, pp.349, 2015 (Journal Indexed in SCI)
- XIII. **The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+breast cancer patients**
BABACAN T., Balakan O., Kuzan T. Y. , Sarici F., Koca E., KERTMEN N., Petekkaya I., Altundag K.
JOURNAL OF BUON, vol.20, pp.50-56, 2015 (Journal Indexed in SCI)
- XIV. **Comparison of three different induction regimens for nasopharyngeal cancer**
KERTMEN N., AKSOY S., CENGİZ M., YAZICI G., KESKİN O., Babacan T., Sarici F., AKIN S., Altundag K., Gullu H. I.
Asian Pacific Journal of Cancer Prevention, vol.16, pp.59-63, 2015 (Journal Indexed in SCI Expanded)

- XV. **A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literature**
Keskin O. D. , KERTMEN N., Karakas Y., BABACAN T., ARIK Z., Altundag K., Gullu I.
JOURNAL OF BUON, vol.20, pp.348, 2015 (Journal Indexed in SCI)
- XVI. **Which sequence best protects the heart against trastuzumab and anthracycline toxicity An electron microscopy study in rats**
KERTMEN N., AKSOY S., ÜNER A., ÖZGÜR Ö., keskin o., babacan t, furkan s., arik z., akın s.
Anticancer Research, 2015 (Journal Indexed in SCI)
- XVII. **Molecular subtypes in patients with inflammatory breast cancer; A single center experience**
KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., ARIK Z., Aslan A., ATEŞ Ö., AKSOY S., et al.
JOURNAL OF BUON, vol.20, pp.35-39, 2015 (Journal Indexed in SCI)
- XVIII. **Association between common risk factors and molecular subtypes in breast cancer patients**
Turkoz F. P. , Solak M., Petekkaya I., Keskin O., KERTMEN N., Sarici F., ARIK Z., BABACAN T., Ozisik Y., Altundag K.
BREAST, vol.22, pp.344-350, 2013 (Journal Indexed in SCI)

Articles Published in Other Journals

- I. **which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in rats**
KERTMEN N.
Hacettepe Journal of Biology and Chemistry, vol.15, pp.1056-1058, 2015 (Other Refereed National Journals)

Refereed Congress / Symposium Publications in Proceedings

- I. **Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience**
AKSOY S., DEĞİRMENCİLER R. F. , AKTAŞ B. Y. , Guven D. C. , AKTEPE O. H. , Guner G., Taban H., KERTMEN N., ARIK Z., DİZDAR Ö.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- II. **Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital**
Güven D. C. , AKTEPE O. H. , Berk Z., Guner G., Taban H., AKTAŞ B. Y. , Duran Z. C. , AKIN Ş., ARIK Z., KERTMEN N., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- III. **TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ**
KERTMEN N., AKSOY S., ERMİŞ D. Y. , KESKİN Ö., SOLAK M., ARIK Z., SARICI F., ATEŞ Ö., ALTUNDAĞ M. K.
22. UKK, Turkey, 19 - 23 April 2017
- IV. **Intravenous ferric carboxymaltose treatment in cancer patients**
ASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- V. **Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma**
ATEŞ Ö., AKSOY S., YETER H. H. , Akın S., KERTMEN N., DİZDAR Ö., TÜRKER F. A. , KARS S. A.
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- VI. **Tumor locations significantly affect disease free survival and overall survival**
BUYUKHATİPOĞLU H., Babacan T., KERTMEN N., Ateş Ö., AKTAŞ G., ŞENDUR M. A. N. , AKSOY S., ÖZİŞİK Y. Y. , ALTUNDAĞ M. K.
2015 ASCO Annual Meeting, 29 May - 02 June 2015

- VII. **Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer**
Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., KARAKAS Y., KILIÇKAP S., AKSOY S., ÖZİŞİK Y. Y. , et al.
ASCO Annual Meeting, 29 May - 02 June 2015
- VIII. **Kadri Altundag Taner Babacan Orhan Efe Ahmet S Hasırcı Fatih Demirci Hakan Buyukhatıpoğlu Ozan Balakan Furkan Saim Sarıcı Neyran Kertmen Ece Esin Serkan Akin Ozturk Ates Sercan Aksoy Ali R Sever**
ALTUNDAĞ M. K. , Babacan T., EFE O., HASIRCI A. S. , DEMİRCİ F., BUYUKHATİPOĞLU H., BALAKAN O., SARICI F. S. , KERTMEN N., ESİN E., et al.
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- IX. **Neuroendocrine breast cancer A single center experience**
TAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., DİZDAR Ö., AKSOY S., ÖZİŞİK Y. Y. , ALTUNDAĞ M. K.
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- X. **Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.**
Altundag K., Babacan T., Efe O., Hasırcı A. S. , Demirci F., Buyukhatıpoğlu H., Balakan O., Sarıcı F. S. , Kertmen N., Esin E., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XI. **Signet ring cell carcinoma of breast: Single center experience.**
AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., Altundag K.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XII. **Correlation of educational status and clinicopathological characteristics of breast cancer: A single center experience.**
Diker O., Babacan T., Buyukhatıpoğlu H., Kertmen N., Balakan O., Sever A. R. , Unlu O., Ates O., Sarıcı S. F. , Akın S., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XIII. **Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats**
Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., Babacan T., Sarıcı S. F. , Sendur M. A. N. , Arik Z., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XIV. **Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.**
Kertmen N., Aksoy S., Cengiz M., Yazıcı G., Keskin O., Babacan T., Sarıcı S. F. , Akın S., Altundag K., Gullu I. H.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XV. **Clinicopathologic characteristics of pure papillary breast carcinoma**
Turkoz F. P. , Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., Aksoy S., Altundag K.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XVI. **Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer.**

Unlu O., Aygun S., Petekkaya H., Gecmez G., Roach E. C. , Babacan T., Sahin U., Keskin O., Kertmen N., Aksoy S., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31
May - 04 June 2013, vol.31

XVII. **The impact of adjuvant delayed radiotherapy (RT) on survival in patients with resected
periampullary adenocarcinomas.**

Yalcin S., Kertmen N., Yuce D., Yildiz F., Hamaloglu E.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31
May - 04 June 2013, vol.31

Citations

Total Citations (WOS):155

h-index (WOS):6